Drugs & Aging

, Volume 30, Issue 7, pp 459–466 | Cite as

Managing Transplant Rejection in the Elderly: The Benefits of Less Aggressive Immunosuppressive Regimens

Current Opinion

Abstract

Organ transplantation is increasingly common in the older population, particularly among end-stage renal disease patients. The outcomes of transplantation are often inferior in older people compared with younger recipients, partly because of the side effects of immunosuppressive medication used after organ transplantation. In this paper, we explore treatment considerations for older transplant patients. The current commonly used immunosuppressive protocols have not been validated sufficiently in older organ recipients. The primary objective for the management of transplant recipients of all ages is to prevent rejection without increasing the risk of infection or other long-term complications. To avoid serious side effects related to immunosuppressive treatment, the clinician should consider modifying and tailoring the long-term regimen for individual patients. Modifications for older recipients include reduction in the dosage or avoidance of calcineurin inhibitors, with or without the introduction of a mammalian target of rapamycin inhibitor and discontinuing the use of corticosteroids. Such modifications must consider the individual risks and needs of each recipient. Treatment of an acute rejection episode should follow the same protocol as for younger recipients, but special attention is needed to ensure reduction in the total immunosuppressive load. One way to achieve this is to avoid anti-thymocyte globulin (ATG) induction and to use on-demand ATG treatment of rejection on the basis of the patient’s CD3 T cell count.

Notes

Acknowledgments

The authors have not received any external financial support for the preparation of this article.

None of the authors reports any conflict of interest.

References

  1. 1.
    Jager KJ, van Dijk PC, Dekker FW, et al. The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol. 2003;60(5):352–60.PubMedGoogle Scholar
  2. 2.
    Kurella M, Covinsky KE, Collins AJ, et al. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med. 2007;146(3):177–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Macrae J, Friedman AL, Friedman EA, Eggers P. Live and deceased donor kidney transplantation in patients aged 75 years and older in the United States. Int Urol Nephrol. 2005;37(3):641–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Port FK, Merion RM, Roys EC, Wolfe RA. Trends in organ donation and transplantation in the United States, 1997–2006. Am J Transpl. 2008;8(4 Pt 2):911–21.Google Scholar
  5. 5.
    Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270(11):1339–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Heldal K, Hartmann A, Grootendorst DC, et al. Benefit of kidney transplantation beyond 70 years of age. Nephrol Dial Transpl. 2010;25(5):1680–7.CrossRefGoogle Scholar
  8. 8.
    Rao PS, Merion RM, Ashby VB, et al. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation. 2007;83(8):1069–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Heldal K, Leivestad T, Hartmann A, et al. Kidney transplantation in the elderly—the Norwegian experience. Nephrol Dial Transplant. 2008;23(3):1026–31.PubMedCrossRefGoogle Scholar
  10. 10.
    McKay D, Jameson J. Kidney transplantation and the ageing immune system. Nat Rev Nephrol. 2012;8:700–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation. 2000;69(5):885–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med. 2011;364(14):1369–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Huang E, Segev DL, Rabb H. Kidney transplantation in the elderly. Semin Nephrol. 2009;29(6):621–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Badowski M, Gurk-Turner C, Cangro C, et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant. 2009;23(6):930–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Heldal K, Hartmann A, Leivestad T, et al. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity. Transplantation. 2009;87(7):1045–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Meier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc. 2001;33(7–8):3425–6.PubMedCrossRefGoogle Scholar
  17. 17.
    de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol. 2001;12(7):1538–46.PubMedGoogle Scholar
  18. 18.
    Oberhuber R, Ge X, Tullius SG. Donor age-specific injury and immune responses. Am J Transplant. 2012;12(1):38–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Pratschke J, Merk V, Reutzel-Selke A, et al. Potent early immune response after kidney transplantation in patients of the European senior transplant program. Transplantation. 2009;87(7):992–1000.PubMedCrossRefGoogle Scholar
  20. 20.
    Knoll GA. Kidney transplantation in the older adult. Am J Kidney Dis. 2012. doi:10.1053/j.ajkd.2012.08.049.
  21. 21.
    Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012;367(21):1972–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Blosser CD, Huverserian A, Bloom RD, et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation. 2011;91(8):858–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Gill J, Sampaio M, Gill JS, et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol. 2011;6(5):1168–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Calne RY. Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet. 1987;2(8557):506–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Fung JJ, Abu-Elmagd K, Todo S, et al. Overview of FK506 in transplantation. Clin Transplant. 1990;115–21.Google Scholar
  26. 26.
    Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2(8670):1000–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–75.PubMedCrossRefGoogle Scholar
  28. 28.
    Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359(9308):741–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001;15(2):89–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Valderhaug TG, Hjelmesaeth J, Jenssen T, et al. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation. 2012;94(7):714–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Merrill JP, Murray JE, Takacs FJ, et al. Successful transplantation of kidney from a human cadaver. JAMA. 1963;185:347–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. Ann Plast Surg. 1984;12(1):70–83.PubMedCrossRefGoogle Scholar
  34. 34.
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345(8961):1321–5.Google Scholar
  35. 35.
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61(7):1029–37.Google Scholar
  36. 36.
    Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60(3):225–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Clayton PA, McDonald SP, Chapman JR, et al. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation. 2012;94(2):152–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Mourer JS, Hartigh J, van Zwet EW, et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation. 2012;93(9):887–94.PubMedCrossRefGoogle Scholar
  39. 39.
    van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86(8):1043–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Arns W, Citterio F, Campistol JM. ‘Old-for-old’—new strategies for renal transplantation. Nephrol Dial Transplant. 2007;22(2):336–41.PubMedCrossRefGoogle Scholar
  41. 41.
    Oyen O, Strom EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant. 2006;6(2):412–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant. 2012;12(6):1528–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Holdaas H, Rostaing L, Seron D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation. 2011;92(4):410–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Mjornstedt L, Sorensen SS, von Zur MB, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant. 2012;12(10):2744–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Snanoudj R, Zuber J, Legendre C. Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs. 2010;70(16):2121–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–57.PubMedCrossRefGoogle Scholar
  47. 47.
    Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6(2):430–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Bock HA, Gallati H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation. 1995;59(6):830–40.PubMedGoogle Scholar
  50. 50.
    Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002;73(3):473–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003;76(5):798–802.PubMedCrossRefGoogle Scholar
  52. 52.
    Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008;85(10):1425–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19(8):629–35.PubMedCrossRefGoogle Scholar
  54. 54.
    Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs. 2001;15(10):655–66.PubMedCrossRefGoogle Scholar
  55. 55.
    Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350(9086):1193–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967–77.PubMedCrossRefGoogle Scholar
  57. 57.
    Morgan RD, O’Callaghan JM, Knight SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012;93(12):1179–88.Google Scholar
  58. 58.
    Tyden G, Ekberg H, Tufveson G, et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation. 2012;94(3):e21–2.PubMedCrossRefGoogle Scholar
  59. 59.
    van den Hoogen MW, Hoitsma AJ, Hilbrands LB. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opin Biol Ther. 2012;12(8):1031–42.PubMedCrossRefGoogle Scholar
  60. 60.
    Midtvedt K, Fauchald P, Lien B, et al. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant. 2003;17(1):69–74.PubMedCrossRefGoogle Scholar
  61. 61.
    Machado S, Figueiredo N, Neves M, et al. Kidney transplantation using donors over 70 years old: are the criteria for organ allocation too expanded? Transplant Proc. 2012;44(8):2289–92.PubMedCrossRefGoogle Scholar
  62. 62.
    Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation. 2008;86(10):1379–83.PubMedCrossRefGoogle Scholar
  63. 63.
    Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326–36.PubMedCrossRefGoogle Scholar
  64. 64.
    Ekberg H, Johansson ME. Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. Transpl Int. 2012;25(11):1119–28.PubMedCrossRefGoogle Scholar
  65. 65.
    Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428–37.PubMedCrossRefGoogle Scholar
  66. 66.
    Johnson DW, Nicol DL, Purdie DM, et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation. 2002;73(7):1158–63.PubMedCrossRefGoogle Scholar
  67. 67.
    Meier-Kriesche HU, Morris JA, Chu AH, et al. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant. 2004;19(11):2864–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Giessing M, Fuller TF, Tuellmann M, et al. Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. World J Urol. 2007;25(3):325–32.PubMedCrossRefGoogle Scholar
  69. 69.
    Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248(4):564–77.PubMedGoogle Scholar
  70. 70.
    Steiner RW. Steroid-free chronic immunosuppression in renal transplantation. Curr Opin Nephrol Hypertens. 2012;21(6):567–73.PubMedCrossRefGoogle Scholar
  71. 71.
    Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;(1):CD003897.Google Scholar
  72. 72.
    Holdaas H, Midtvedt K, Asberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf. 2012;11(6):1013–22.PubMedCrossRefGoogle Scholar
  73. 73.
    Heldal K, Hartmann A, Leivestad T, et al. Risk variables associated with the outcome of kidney recipients >70 years of age in the new millennium. Nephrol Dial Transplant. 2011;26(8):2706–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009;69(11):1483–512.PubMedCrossRefGoogle Scholar
  75. 75.
    Patel SJ, Knight RJ, Suki WN, et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant. 2011;25(3):E250–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Clinic of Internal MedicineTelemark HospitalSkienNorway
  2. 2.Department of Organ Transplantation, Section of NephrologyOslo University Hospital RikshospitaletOsloNorway

Personalised recommendations